Literature DB >> 3403990

An alternate method utilizing small quantities of ligand for affinity purification of monospecific antibodies.

H N Aithal1, K M Knigge, S Kartha, E A Czyzewski, F G Toback.   

Abstract

An alternate method was designed to couple a limited quantity of protein to an affinity support when a conventional technique was unsuccessful. This was achieved through the introduction of a small number of sulfhydryl groups to the ligand by reaction with 2-iminothiolane which resulted in a limited number of reactive sites on the protein. Amino groups on an AH-Sepharose 4B matrix were linked to sulfhydryl groups on the ligand using the heterobifunctional agent m-maleimidobenzoyl sulfosuccinimide ester (sulfo-MBS). This method was employed to prepare an affinity support using a cytosolic protein that activates glyceraldehyde-3-phosphate dehydrogenase as a ligand. Monospecific antibody purified from the affinity column recognized only this protein on a Western blot of a cytosolic extract of kidney epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3403990     DOI: 10.1016/0022-1759(88)90034-8

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

1.  CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells.

Authors:  I I Singer; S Scott; D W Kawka; J Chin; B L Daugherty; J A DeMartino; J DiSalvo; S L Gould; J E Lineberger; L Malkowitz; M D Miller; L Mitnaul; S J Siciliano; M J Staruch; H R Williams; H J Zweerink; M S Springer
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Affinity-based separations and purifications. Patents and literature.

Authors:  J S Dordick
Journal:  Appl Biochem Biotechnol       Date:  1991-01       Impact factor: 2.926

3.  Immunoassays for pentamidine and related compounds: development of a facile inhibitory ELISA suitable for clinical use.

Authors:  H M Reisner; D R Gray; S K Jones; B G Rose; R R Tidwell
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.